Business Wire

SAMSUNG-ELECTRONICS

17.1.2023 10:06:47 CET | Business Wire | Press release

Share
Samsung Introduces the 200-Megapixel Image Sensor for the Ultimate High Resolution Experience in Flagship Smartphones

Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today introduced its latest 200-megapixel (MP) image sensor, the ISOCELL HP2, with improved pixel technology and full-well capacity for stunning mobile images in tomorrow’s premium smartphones.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230117005554/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Samsung Introduces the 200-Megapixel Image Sensor for the Ultimate High Resolution Experience in Flagship Smartphones (Graphic: Business Wire)

"The Samsung ISOCELL HP2 harnesses Samsung's high-resolution image sensor technologies and know-how at the cutting edge for epic details," said JoonSeo Yim, Executive Vice President of Sensor Business Team at Samsung Electronics. "Our leadership comes from innovative pixel technologies that allow our sensors to go beyond the number and size of pixels. We will continue to open new horizons and solidify our presence in the expanding ultra-high-resolution sensor market."

The ISOCELL HP2 packs 200-million 0.6-micrometer (μm) pixels in a 1/1.3” optical format, a sensor size that is widely used in 108MP main smartphone cameras. This enables consumers to enjoy even higher resolutions in the latest high-end smartphones without larger camera bumps in their devices.

With Samsung’s advanced pixel-binning technology, Tetra2pixel, the HP2 adds more versatility to the camera as it simulates different pixel sizes to accommodate varying lighting levels. When in low-lit environments, the sensor transforms either into a 1.2μm 50MP or 2.4μm 12.5MP image sensor by binding four to 16 neighboring pixels. For fuller 8K video, approximately at 33MP, the HP2 switches to 1.2μm 50MP mode to minimize cropping and capture more of the scene. Filming 8K at 30 frames-per-second (fps), a wide field of view along with bigger pixel size can produce sharp cinematic videos.

Washed out pictures from brightly lit environments can be significantly reduced with the HP2, thanks to Samsung’s new Dual Vertical Transfer Gate (D-VTG) technology. In a photo diode within each pixel, a voltage transfer gate is placed on the bottom to transport electrons from the pixels to the logic layer. With high precision, D-VTG adds a second transfer gate in the pixel, boosting the pixel’s full-well capacity by more than 33 percent. With more electrons stored and efficient signal transfers, this method can reduce overexposure and enhance color reproduction, especially in bright light conditions

In low-lit settings, the HP2’s auto-focusing is taken to the next level with Super QPD, which allows the sensor to use all its 200-million pixels for focusing agents. The ample amount of focusing agents are grouped by four adjacent pixels to recognize both horizontal and vertical pattern changes that delivers faster and more accurate auto-focusing. Utilizing the rich pattern data along with the sheer number of reference points, the new sensor is capable of fast auto-focusing, even in a dimly lit environment.

For superb HDR performance, Samsung is introducing the DSG feature for the first time in 50MP mode which applies two separate conversion values to the analog signal received at the pixel level. In addition, the Smart-ISO Pro, an HDR solution that merges different levels of ISO readouts from a single exposure, allows the camera to take 12.5MP images and 4K at 60fps video in HDR.

The Samsung ISOCELL HP2 has entered mass production.

About Samsung Electronics Co., Ltd.

Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at news.samsung.com.

# # #

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005554/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SOLUM and Simbe Expand European Collaboration to Advance Intelligent Store Operations5.3.2026 08:00:00 CET | Press release

SOLUM (KOSPI: 248070) and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. The collaboration was highlighted at EuroShop, where Simbe’s Store Intelligence™ platform was demonstrated live at the SOLUM booth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304620371/en/ SOLUM and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. (Image: SOLUM) Simbe recently introduced Tally 4.0, the next generation of their autonomous shelf-scanning robot, reflecting the company’s continued evolution in retail shelf digitization, incorporating extended runtime, enhanced edge computing, and advanced vision capabilities. Designed to deliver deeper shelf coverag

Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology5.3.2026 08:00:00 CET | Press release

Breakthrough designation means Cognita™ will engage in prioritized interaction with FDA regarding clearance of device designed to help solve the radiology capacity bottleneck Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing generative vision-language models (VLMs) for radiology, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Cognita Chest X-Ray (CXR)™1 across multiple critical indications. Cognita CXR is an industry-first generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted this designation2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304633206/en/ Cognita™ operates as the AI business unit of Mosaic Clinical Technologies™, a

Cielo Advances Resilient Remote Connectivity for Its Nationwide Payment Terminal Fleet With Thales5.3.2026 08:00:00 CET | Press release

Cielo, one of Brazil’s leading payment service providers, is piloting remote connectivity management for its point-of-sale (POS) terminals across the country, in partnership with Thales. By deploying Thales’s eSIM connectivity management platform based on the latest GSMA SGP.32 IoT standard, Cielo is accelerating its transition from manual, on-site SIM management to fully remote, secure and resilient connectivity. For Cielo, connectivity is mission critical. When payment terminals lose network access, transactions stop. To strengthen operational resilience and enhance merchant experience, Cielo is modernizing its connectivity architecture across its terminal fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304089321/en/ Cielo advances resilient remote connectivity for its nationwide payment terminal fleet with Thales. Using Thales’s eSIM technology as part of this strategy, Cielo can remotely switch mobile network op

GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.5.3.2026 08:00:00 CET | Press release

GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224658973/en/ Dr. Mario Weiss, Founder & CEO of GAIA AG This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s highly scientific experience in cardiovascular risk management and health. Together, the partners - both members of the German Association of Research-Based Pharmaceutical Companies (vfa) - aim to address a persistent gap in chronic care: leveraging digital technologies to make a difference in patients’ lives by supporting sustainable, long-term behaviour change. Expanding Cardiovasc

Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency1, and Core EBITDA2 of 1.211 billion USD, Growing 18.9% at Constant Currency5.3.2026 07:00:00 CET | Press release

Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume. Broad-based net sales growth, growing double-digits in both International markets and the U.S. Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency. Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new produ

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye